Voyager Therapeutics, Inc. (VYGR) stock
Close on Nov 13, 2026Market cap $106.60MP/E –Yield –
Earnings
Voyager Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Voyager Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026during market hours | $3.20M | -38.5% | -$0.40 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026during market hours | $2.60M | -60.0% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 9, 2026during market hours | $15.30M | +142.9% | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025before the open | $13.40M | -45.5% | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025during market hours | $5.20M | -82.4% | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025during market hours | $6.50M | -66.7% | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 11, 2025during market hours | $6.30M | -93.0% | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024during market hours | $24.60M | +434.8% | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024during market hours | $29.60M | +504.1% | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 13, 2024during market hours | $19.50M | -87.0% | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024during market hours | $90.10M | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 6, 2023during market hours | $4.60M | -88.8% | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023before the open | $4.90M | +600.0% | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023before the open | $150.50M | +21400.0% | $2.94 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 7, 2023before the open | -$1.55M | -105.5% | -$0.61 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022before the open | $41.10M | +2640.0% | $0.45 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022during market hours | $700.00K | – | -$0.50 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022during market hours | $700.00K | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 8, 2022before the open | $28.10M | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 2, 2021before the open | $1.50M | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 9, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 10, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 9, 2020during market hours | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 10, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
No open guidance: every period Voyager Therapeutics guided for has been reported
Guidance history
Every forecast Voyager Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 2, 2021 | cash, cash equivalents, and marketable debt securities | FY2021 | $130.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Voyager Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Update
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
See a number that looks wrong?